Gilead Keeps Close Eye On Stormy Remdesivir Situation In India
Gilead is closely evaluating the situation for remdesivir in India as the country tackles shortages of the drug, which has several local licensees, with instances of black marketing adding to the local woes. The US firm clearly will not want any momentum towards possible compulsory licensing as initiated by Hungary and Russia, even as Indian firms have cut prices of the antiviral.
You may also be interested in...
Sun Pharma's senior leadership talks to Scrip about the focus in India on differentiated therapies; the challenges of holding adequate 'strategic inventory' amid waves of the pandemic; and where things stand for active pharmaceutical ingredients. India’s top ranked drug firm is apparently not averse to a role in COVID-19 vaccine distribution, either.
Senior Kroll executive outlines sharp shifts in scope of integrity and reputational due diligence in the healthcare and life sciences sector post COVID-19, with investors now seeking "very micro" insights of target firms.
Unless Pfizer or Moderna beat the company to it, Zydus Cadila’s COVID-19 vaccine candidate could be India’s first such jab approved for children. With superior thermostability and proposed economical pricing, it will be one to watch, though a three-dose regimen could be a dampener. Meanwhile, saroglitazar sees slow progress.